GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Does Insurance Cover Stem Cell Therapy?

Short answer: Insurance may cover a stem cell transplant for an eligible blood cancer or blood disorder, but it usually does not cover clinic injections sold for knee pain, back pain, or anti-aging. The answer depends on the exact treatment, diagnosis, country, and health plan—not the words “stem cell therapy.” Approval of a product does not automatically mean your insurer will pay.

Blood-forming stem cell transplantation is an established treatment for selected patients with leukemia, lymphoma, multiple myeloma, and certain noncancerous blood disorders Stem cell transplant. In the United States, Medicare covers specified transplant indications under a national policy; the cell source and eligibility conditions matter Ncd.aspx?NCDId=366.

Does Insurance Cover Stem Cell Therapy?

The FDA also approves individual cell and gene therapy products for defined diseases Approved cellular and gene therapy products. That is different from approving a clinic’s general stem cell injection service. The FDA’s consumer warning identifies unapproved regenerative products marketed for conditions such as knee osteoarthritis and back pain Important patient and consumer information about regenerative medicine therapies. For these injections, ask your plan specifically about its experimental or investigational exclusion before paying a deposit.

The coverage rules below focus on the United States, followed by Japan and England. They are not interchangeable across countries.

One phrase, several different treatments

“Stem cell therapy” can describe very different services. A coverage decision needs a treatment or product name and a diagnosis.

Hematopoietic stem cell transplantation (HSCT). Blood-forming stem cells are infused to restore blood production after conditioning treatment, which may include chemotherapy or radiation. Cells come from the patient (autologous) or a donor (allogeneic). Risks include infection, infertility, organ damage, and graft-versus-host disease when donor cells are used. Conditioning and risks vary by transplant regimen Stem cell transplant.

FDA-approved cell and gene therapies. Some use modified blood-forming stem cells, including therapies for sickle cell disease. Others do not: CAR-T treatment uses immune T cells, not stem cells. These treatments are discussed here because readers may encounter them alongside transplant services. Each product has its own approved indication and eligibility criteria; they are not one interchangeable “stem cell” benefit Approved cellular and gene therapy products.

Clinical trial interventions. A legitimate trial can still involve an unapproved product. Insurance may cover eligible routine patient care without paying for the research product. Ask the study team which costs go to the sponsor, the insurer, or you Paying. For a US cell-product trial, ask about its investigational new drug (IND) status and institutional review board (IRB) review.

Clinic procedures sold as stem cell therapy. Examples include fat- or bone-marrow-derived joint injections and IV wellness infusions. A clinic’s registration, a trial listing, or use of your own cells does not establish FDA approval or insurance coverage Important patient and consumer information about regenerative medicine therapies. Japan has a separate regulatory framework, discussed below.

Type Example Regulatory status Typical insurance answer
Blood stem cell transplant Bone marrow or peripheral blood transplant for acute myeloid leukemia Standard treatment for selected patients Stem cell transplant Often covered when criteria are met Ncd.aspx?NCDId=366
Approved cell or gene therapy CAR-T for relapsed large B-cell lymphoma; gene therapy for sickle cell disease FDA-approved for specific indications Approved cellular and gene therapy products Coverage criteria depend on the product and plan Ncd.aspx?NCDId=374 PMC12481358
Clinical trial Investigational mesenchymal cell product for an autoimmune disease Trial under IND and IRB review Routine costs sometimes covered; product usually not Paying Ncd.aspx?ncdid=1 S300gg 8
Private clinic injection Cultured fat-derived cells for knee osteoarthritis; IV cells for fatigue Not equivalent to an approved product for that diagnosis Important patient and consumer information about regenerative medicine therapies Do not assume coverage; request the plan’s written investigational-treatment policy

When insurance usually pays

Blood and marrow transplants

The NCI’s explanation of transplant treatment is not an insurance coverage list. A medically established use does not by itself establish your benefit Stem cell transplant.

Medicare’s NCD 110.23, effective March 6, 2024, includes donor-cell HSCT for leukemia, aplastic anemia, severe combined immunodeficiency, Wiskott-Aldrich syndrome, and myelodysplastic syndromes meeting specified risk-score criteria. Autologous coverage includes selected cases of acute leukemia in remission, resistant non-Hodgkin lymphoma, recurrent or refractory neuroblastoma, advanced Hodgkin disease, multiple myeloma, and primary AL amyloidosis. Each indication has conditions; a diagnosis alone is not enough Ncd.aspx?NCDId=366.

For donor-cell HSCT in multiple myeloma, myelofibrosis, and severe symptomatic sickle cell disease, Medicare’s national policy requires participation in an approved prospective clinical study and satisfaction of its disease-specific criteria. This is coverage with evidence development, not unrestricted coverage. The same policy explicitly excludes some uses, including autologous transplantation for most solid tumors and tandem autologous transplantation for multiple myeloma. Local Medicare Administrative Contractors decide only indications not already specified as covered or noncovered Ncd.aspx?NCDId=366.

Under this policy, coverage of a transplant includes its necessary mobilization, harvesting, conditioning, and transplant steps. If that transplant is noncovered, those steps are not covered as part of it. This does not mean unrelated, otherwise-covered medical care is automatically excluded Ncd.aspx?NCDId=366.

Commercial plans are not bound by Medicare’s coverage rule. They write their own medical policies. Request the written policy and check which guideline it cites. Even when a plan covers the same transplant for the same diagnosis, it can still require prior authorization, a specific transplant center, or a second opinion.

Approved cell and gene therapies

Casgevy and Lyfgenia are examples of approved, stem-cell-based gene therapies for defined patients with sickle cell disease. Their approval does not extend to unrelated diseases or clinic injection protocols Approved cellular and gene therapy products.

Medicare’s CAR-T policy covers qualifying autologous cancer treatment with an FDA-approved product for an approved indication or another use supported by a CMS-approved compendium Ncd.aspx?NCDId=374. Older coverage summaries mention a facility’s enrollment in an FDA Risk Evaluation and Mitigation Strategy (REMS). That requirement is outdated: CMS removed the REMS-facility and related Part B KX-modifier requirements for services from June 26, 2025 Mm14204 chimeric antigen receptor t cell therapy claims end risk evaluation mitigation strategy kx.pdf. The FDA eliminated REMS for the six listed BCMA- and CD19-directed autologous CAR-T products; their serious-risk warnings and safety monitoring remain Fda eliminates risk evaluation and mitigation strategies rems autologous chimeric antigen receptor.

A 2025 JAMA study examined December 2024 policies from 18 large commercial plans representing about 70% of the commercially insured market. Among 541 indication-plan policies for approved cell and gene therapies, 9 (1.7%) denied coverage outright. Of the remaining 532, 276 (51.9%) imposed restrictions beyond FDA labeling. These are policy counts—not a patient’s probability of approval. The study did not measure actual access or appeal outcomes PMC12481358.

A covered listing may still come with additional patient criteria or a requirement to try another treatment first. Ask for the current policy rather than assuming the FDA label is the plan’s complete eligibility test PMC12481358.

For sickle cell gene therapy, CMS created the Cell and Gene Therapy Access Model. At the July 2025 announcement, 33 states plus DC and Puerto Rico were participating, covering about 84% of Medicaid beneficiaries with sickle cell disease. CMS negotiates the agreements with manufacturers, and payment is tied to outcomes Cms expands access lifesaving gene therapies through innovative state agreements. Participation varies, so check whether your state takes part and what prior authorization it requires Cms expands access lifesaving gene therapies through innovative state agreements.

Clinical trials

Trial billing separates routine care from research-only costs. Sponsors often pay research costs, but not always. Obtain the study’s written cost breakdown rather than assuming participation is free Paying.

Medicare pays routine costs in qualifying trials, including care for complications. It does not pay for the experimental item itself unless that item is otherwise covered, and it does not pay for tests performed only to collect data Ncd.aspx?ncdid=1.

For plans subject to the ACA clinical-trial provision, eligible patients in approved trials for cancer or another life-threatening disease have protections for routine patient costs. The law does not require payment for the investigational item or require out-of-network benefits the plan otherwise lacks. Do not assume every trial or every plan qualifies S300gg 8.

Ask the trial coordinator for a written budget before enrolling. The budget should show which scans, visits, and drugs are billed to insurance, which costs the sponsor pays, and what happens to billing if participation ends early.

HSCT for multiple sclerosis

Coverage for autologous HSCT (AHSCT) in MS is narrow. On the NHS, access stays limited to treatment-resistant, inflammatory-active MS, and every candidate’s case goes before a specialist transplant meeting Pn 2024 004228. The Association of British Neurologists backs this option under agreed criteria for people with highly active relapsing MS that hasn’t responded to standard disease-modifying drugs.

AHSCT is not routine care for progressive MS without inflammatory activity Pn 2024 004228. Its risks include infections, fertility effects, and transplant complications Stem cell transplant. Medicare leaves transplant indications not otherwise specified as covered or noncovered to local contractors Ncd.aspx?NCDId=366. For commercial plans, request the written MS-specific criteria and appeal procedure.

When insurance usually says no

Knee and back injections

Clinics advertise “stem cell therapy” for knee osteoarthritis, torn rotator cuffs, disc disease, and back pain. The FDA has not approved any stem cell product for an orthopedic condition Important patient and consumer information about regenerative medicine therapies.

In the ADIPOA2 phase 2b randomized trial, 135 patients with mild-to-moderate knee osteoarthritis were assigned to a single injection into the joint of their own adipose-derived mesenchymal stromal cells (2 million or 10 million cells) or saline; 97 were analyzed. At six months, 47.3% of the combined cell groups and 54.8% of the placebo group met the prespecified strict OARSI/OMERACT criteria for symptom response. The difference was not statistically significant (relative risk 0.86, 95% confidence interval 0.58–1.28; P=.46). Pain and function did not differ significantly over 12 months. Adverse events were reported as similar between groups; this does not establish safety for other products or longer follow-up J.ard.2025.07.026.

The study tested one product and did not reach its planned enrollment. It does not establish cartilage repair or settle the evidence for every cell product. It is also not an insurance policy: request your plan’s separate coverage determination J.ard.2025.07.026.

Medicare’s blood-forming stem cell transplant policy is not a coverage pathway for a clinic’s knee or back injection Ncd.aspx?NCDId=366. A “superbill,” diagnosis code, or unlisted procedure code does not itself establish reimbursement.

Anti-aging and wellness

Do not treat a wellness or anti-aging package as an approved medical indication. Ask the clinic for the exact product and its approved use, and ask the insurer whether the requested service is excluded as cosmetic, experimental, or investigational. The FDA warning describes risks from unapproved regenerative products Important patient and consumer information about regenerative medicine therapies.

The FDA has reported blindness, tumor growth, serious infections, and immune reactions after unapproved regenerative products Important patient and consumer information about regenerative medicine therapies. Claims that cells from the patient’s own body carry no risk omit the harvesting procedure, the laboratory processing, the route of administration, and the risk of contamination.

Unapproved treatment

The FDA warns that charging patients for unapproved regenerative products outside a properly overseen trial is often illegal. It also warns that a ClinicalTrials.gov listing — or an FDA registration — doesn’t make a product legally marketed Important patient and consumer information about regenerative medicine therapies.

For a US investigational cell-product trial, ask the study team about its IND, institutional review board (IRB) oversight, and consent form. An IND is permission to investigate a product, not evidence that it works. Other countries have different oversight systems.

How insurers decide

The table below turns the coverage question into five checks, with the documents each check needs.

Question What it means What to send
Is the service a covered benefit? The plan document lists the category of care. Some plans exclude experimental, investigational, or cosmetic treatment. The plan’s Summary Plan Description or Evidence of Coverage, and the exact procedure name.
Is it medically necessary? The treatment must be appropriate for your diagnosis, severity, and prior treatment history. Doctor’s letter, medical records, imaging, lab results, failed alternatives, and clinical guidelines.
Is it experimental or investigational? A plan may exclude the requested use even if a product has approval for something else. An IND permits investigation; it is not marketing approval. Product label for an approved use, or trial documentation for an investigational use; relevant studies and guidelines.
Is the provider in network? The hospital, doctor, and sometimes the cell-processing lab must meet plan rules. Provider National Provider Identifier (NPI), facility name, network status, and site-of-care review.
Was prior authorization obtained? Some services require approval before treatment. A written authorization number, approved dates, and the exact services approved.

Obtain separate written confirmation for the facility, the physician, and the product, since approval of one does not imply approval of the others. Ask the insurer to list each approved CPT/HCPCS code, revenue code, and drug code.

Prior authorization is not a payment guarantee. HealthCare.gov explicitly warns that preauthorization does not promise the plan will cover the cost Preauthorization. Ask separately about benefit eligibility, exclusions, network status, and your estimated share. A clinic’s cash price and an insurer’s allowed amount may not be the same.

United States

Employer plans

For employer-sponsored coverage, request the governing plan documents, the Summary Plan Description, and any insurance certificate. Ask the plan administrator to explain differences between a summary and the underlying terms. The insurance card and the clinic’s billing office do not determine coverage.

Ask HR whether the plan is self-funded. If it is, state coverage mandates may not apply 14 01. Under ERISA, self-insured plans generally are not subject to state health insurance laws, including coverage mandates 14 01. Federal claims and appeals rules still apply, but the state insurance department may be unable to intervene. Ask HR which entity administers claims.

ACA marketplace plans

Marketplace plans must cover essential health benefits and follow ACA protections, including the clinical-trial provision S300gg 8 and appeal rights Internal appeals. Before enrolling, review the plan’s ‘experimental’ exclusions, transplant network, and drug formulary.

Medicare

Original Medicare covers HSCT under NCD 110.23 Ncd.aspx?NCDId=366 and FDA-approved CAR-T under NCD 110.24 Ncd.aspx?NCDId=374. It generally does not require prior authorization for these services, but deductibles, coinsurance, and copays still apply. A Medigap supplement may help with cost-sharing; it does not add coverage for excluded services.

Medicare Advantage plans must cover all medically necessary services that Original Medicare covers. They may require prior authorization and use a network Compare original medicare medicare advantage. For authorization rules, contact the plan rather than Medicare.

Medicaid

Medicaid is administered by each state. Transplant and gene therapy coverage varies by state, and prior authorization is common. The NCI notes that Medicaid covers routine patient costs in a clinical trial Paying. The CMS access model may apply to sickle cell gene therapy if the state participates Cms expands access lifesaving gene therapies through innovative state agreements.

VA and TRICARE

The NCI notes that eligible veterans can take part in NCI-sponsored trials at VA medical centers, and that TRICARE may reimburse medical costs for those trials Paying. Coverage outside a trial follows VA or TRICARE benefit rules rather than Medicare rules.

Japan

For someone enrolled in Japan’s public health insurance, the question is whether the exact treatment is an insured service—not simply whether a clinic is legally providing it.

TEMCELL HS illustrates a narrow approved indication. Japan approved this donor bone-marrow-derived mesenchymal cell product in September 2015 for acute graft-versus-host disease after hematopoietic stem cell transplantation. The approved product is administered intravenously, and the approval requires an experienced transplant team and a use-results survey 000215658.pdf. This approval does not cover knee arthritis, anti-aging, or wellness infusions.

Japan also has a designated “advanced medical care” category. For qualifying care at an eligible facility, the advanced technology fee is self-pay while the ordinary insured portion can remain covered. MHLW illustrates a ¥1,000,000 bill with a ¥200,000 advanced-care fee: at a 30% copayment on the remaining ¥800,000, the patient pays ¥200,000 + ¥240,000 = ¥440,000. This is a general billing illustration, not a stem cell treatment price or an entitlement for every regenerative procedure; actual copayments and benefit adjustments depend on eligibility Index.

Care outside an approved product or its approved indication is generally self-pay, including cultured-cell plans that are not approved products. Japan’s Act on the Safety of Regenerative Medicine requires providers to file a treatment plan, obtain review by a certified committee, and follow safety and consent rules. Techniques are classified by risk level En. Filing is a safety and transparency procedure; it is not PMDA approval and does not establish efficacy.

Patients considering treatment in Japan should check the exact plan in the health ministry’s public provider list 0000186471 and request written confirmation of the regulatory route, the total price, and the refund policy. The site’s guide to Japanese health insurance for foreign patients explains the residency and copayment rules in more detail.

Visitors without enrollment in Japan’s public insurance generally pay the full cost themselves Newpage_46516. A clinic statement that “insurance may cover it” does not establish coverage; request the billing route in writing.

Considering treatment in Japan? Ask for the regulatory route, full written quote, and refund terms before you pay.

Ask About Treatment in Japan

England: NHS coverage

NHS England updated its policy in September 2025. It commissions HSCT for indications classed as standard of care or a clinical option by the UK transplant society, BSBMTCT. Indications classified as developmental or generally not recommended are not routinely commissioned, although an individual funding request may be considered Haematopoietic stem cell transplantation all ages.

This is an England commissioning policy, not a single UK-wide entitlement. Scotland, Wales, and Northern Ireland have separate arrangements. Ask the treating NHS center which policy applies; private availability does not establish NHS funding.

Travel insurance and cross-border care

Do not assume ordinary travel insurance funds planned treatment abroad. Ask the insurer to identify any planned-treatment exclusion and explain whether a medical-travel benefit is needed. Your domestic health plan’s foreign-care rules are a separate question; home-country coverage does not establish overseas reimbursement.

Before you travel for treatment, check whether the policy:

  • covers planned or elective treatment;
  • covers complications from a procedure that the policy excludes;
  • covers pre-existing conditions;
  • pays the hospital directly or reimburses you later;
  • covers medical evacuation and repatriation;
  • has a time limit for claims after you return home.

Obtain written confirmation of exclusions before paying. After a procedure abroad, retain the itemized bill, the discharge summary, and a letter stating the diagnosis, procedure, and any complications.

How to check your own coverage

A practical scenario—not a patient case: A clinic says it can give you an itemized bill for a knee injection. That tells you what it plans to charge, not what your insurer covers. Ask the clinic for the exact product, diagnosis, procedure codes, and facility details; then send that same description to the insurer. If the plan says “experimental treatment excluded,” ask which policy and clause it applied before paying a deposit. Even an authorization letter is not a promise of payment Preauthorization.

  1. Get the exact treatment description. Record the product name, cell source (autologous or allogeneic), dose, route, and number of sessions. Note whether the product is FDA-approved, offered under an IND, or neither. The term “stem cells” alone does not identify a billable service.
  2. Get the billing codes. For US claims, collect the ICD-10 diagnosis code, procedure billing codes (CPT or HCPCS), any drug codes, and revenue codes for hospital care. Other countries use different coding systems. Give the insurer the codes the provider actually plans to bill.
  3. Read the plan document. Review the sections on experimental or investigational treatment, medical necessity, prior authorization, out-of-network care, and foreign care. The Summary Plan Description or Evidence of Coverage contains more detail than the member handbook.
  4. Call the insurer and document the answers. Ask whether the exact code is covered for the diagnosis, whether prior authorization is required, whether the provider and facility are in network, and what cost-sharing applies after deductible and coinsurance. Record the date, the representative’s name, and the reference number.
  5. Request any required authorization in writing. Have the treating team submit the physician letter, records, product label, and supporting evidence; include trial documentation when relevant. Check the approved services, dates, conditions, and estimated patient share. A predetermination or authorization is not a substitute for checking the actual benefit Preauthorization.
  6. Get a written quote from the clinic. The quote should separate medical fees from travel, lodging, and interpretation. Clarify the policy if treatment is cancelled, the cells fail release criteria, or a repeat administration is needed.
  7. Confirm the network and site of care. Network status can differ between the surgeon and the hospital, or between a consultation and the procedure at the same clinic. Confirm each separately.
  8. Keep all records. Retain the denial letter, the appeal, the approval, the bills, and the medical records for further appeals or tax documentation.

If you are denied

Read the denial letter and identify the stated reason: not a covered benefit, not medically necessary, experimental or investigational, out of network, or missing prior authorization.

For an ACA-covered plan, an internal appeal must be filed within 180 days. The plan must decide within 30 days for a pre-service appeal and 60 days for a post-service appeal; urgent appeals are decided within 72 hours Internal appeals. If the internal appeal is unsuccessful, external review — including denials based on an “experimental” or “investigational” determination — may be requested within four months. A standard external review is decided within 45 days and an expedited review within 72 hours, and the insurer must accept the decision External review.

With a self-funded employer plan, the appeal follows federal ERISA rules. The state insurance department may lack jurisdiction, but the plan must still follow the federal claims and appeals process. Ask HR for the appeal procedure and the claims administrator’s contact information.

Original Medicare appeals proceed through redetermination by the Medicare contractor, reconsideration, an administrative law judge hearing, the Medicare Appeals Council, and federal court. In Medicare Advantage, the appeal starts with the plan’s own process, and the decision letter explains the next level How do i file an appeal. State Health Insurance Assistance Program (SHIP) counselors provide free help with these appeals.

For Medicaid, the state agency explains the fair-hearing process. Deadlines and procedures vary by state.

A complete appeal file includes the patient name and member ID, diagnosis and ICD-10 code, requested service and CPT/HCPCS code, physician letter of medical necessity, the product label or trial documents as appropriate, supporting studies and guidelines, prior treatments tried, and the requested outcome. Include the denial letter and the plan policy. Trial paperwork does not turn an investigational product into an approved treatment.

Red flags in clinic marketing

  • “Insurance will cover it.” Ask for a written verification from your insurer, not the clinic.
  • “FDA registered” or “FDA approved.” Registration is not approval. Ask for the product name and the approved indication.
  • “Clinical trial” without documented oversight. For a US investigational cell-product trial, ask the study team about its IND and IRB review. A registry listing alone proves neither efficacy nor insurance eligibility Important patient and consumer information about regenerative medicine therapies.
  • “Approved in Japan.” Ask whether that means a PMDA-approved product or a filed provision plan under the Act on the Safety of Regenerative Medicine 000215658.pdf En.
  • “Stem cells can treat almost anything.” Approval belongs to a specific product and indication, not to stem cells as a universal treatment Approved cellular and gene therapy products.
  • “No risk, no side effects.” The FDA has reported serious infections, tumors, blindness, and immune reactions Important patient and consumer information about regenerative medicine therapies.
  • “Pay cash and we’ll help you get reimbursed.” A superbill is not a coverage guarantee.
  • “Patient-funded trial.” Charging the patient for an unapproved product outside a properly overseen trial is a warning sign Important patient and consumer information about regenerative medicine therapies.
  • Testimonials instead of data. A before-and-after photo is not a clinical trial.
  • Pressure to decide today. Ask for the second opinion and the written quote before you pay a deposit.

Bottom line

Insurance can cover an eligible blood-forming stem cell transplant or a specific approved cell or gene therapy. It is not general reimbursement for anything advertised as “stem cell therapy.” Medicare’s transplant rules specify covered uses, study-only coverage, and exclusions Ncd.aspx?NCDId=366. Commercial coverage has its own restrictions: the JAMA study found extra conditions in 51.9% of the 532 policies that did not deny coverage outright, not a 51.9% patient-denial rate PMC12481358.

Before paying, match the clinic’s proposed treatment to your plan’s written benefit and exclusions. Obtain any required authorization and an estimate of what you owe, but do not treat either a clinic’s reassurance or authorization alone as guaranteed reimbursement Preauthorization.

This article is general information, not individualized medical or insurance advice. Sources were consulted on October 24–27, 2026; access dates are listed below. Coverage rules and product labels change. Confirm clinical suitability with your treating specialist and the current benefit with your insurer before treatment.

Sources

  1. National Cancer Institute. Stem Cell and Bone Marrow Transplants for Cancer. Source (accessed October 24, 2026).
  2. Centers for Medicare & Medicaid Services. National Coverage Determination 110.23: Stem Cell Transplantation (Formerly 110.8.1). Effective March 6, 2024. Source (accessed October 24 and rechecked October 27, 2026).
  3. U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. Source (accessed October 24, 2026).
  4. U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. June 3, 2021. Source (accessed October 24, 2026).
  5. National Cancer Institute. Who Pays for Clinical Trials? Source (accessed October 24, 2026).
  6. Centers for Medicare & Medicaid Services. National Coverage Determination 110.24: Chimeric Antigen Receptor (CAR) T-cell Therapy. Effective August 7, 2019. Source (accessed October 24, 2026).
  7. Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene Therapies. JAMA. Published online September 29, 2025. Source (accessed October 24 and rechecked October 27, 2026).
  8. Centers for Medicare & Medicaid Services. National Coverage Determination 310.1: Routine Costs in Clinical Trials. Effective July 9, 2007. Source (accessed October 24, 2026).
  9. 42 U.S.C. § 300gg-8: Coverage for individuals participating in approved clinical trials. Source (accessed October 24, 2026).
  10. Centers for Medicare & Medicaid Services. MLN Matters MM14204: Chimeric Antigen Receptor T-Cell Therapy Claims: End of Risk Evaluation Mitigation Strategy & KX Modifier Requirement. Released December 9, 2025; effective June 26, 2025; implementation February 6, 2026. Source (accessed October 27, 2026).
  11. U.S. Food and Drug Administration. FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. June 26, 2025. Source (accessed October 27, 2026).
  12. Centers for Medicare & Medicaid Services. CMS Expands Access to Lifesaving Gene Therapies Through Innovative State Agreements. July 15, 2025. Source (accessed October 24, 2026).
  13. Association of British Neurologists. Using disease-modifying treatments in multiple sclerosis: ABN 2024 guidance. Practical Neurology. Published online November 11, 2024. Source (accessed October 24, 2026).
  14. Effect of intra-articular adipose-derived mesenchymal stromal cell versus placebo injection on pain and function in patients with knee osteoarthritis: the ADIPOA2 phase 2b randomised clinical trial. Annals of the Rheumatic Diseases. Published online August 29, 2025. Source (accessed October 24, 2026).
  15. HealthCare.gov. Preauthorization. Source (accessed October 27, 2026).
  16. U.S. Department of Labor. Technical Release No. 2014-01. November 6, 2014. Source (accessed October 24, 2026).
  17. HealthCare.gov. Internal Appeals. Source (accessed October 24, 2026).
  18. Medicare.gov. Compare Original Medicare & Medicare Advantage. Source (accessed October 24, 2026).
  19. Pharmaceuticals and Medical Devices Agency (Japan). Report on the Deliberation Results: TEMCELL HS Inj. August 11, 2015. Source (accessed October 24, 2026).
  20. Ministry of Health, Labour and Welfare (Japan). Advanced Medical Care overview. Source (accessed October 24, 2026).
  21. Ministry of Health, Labour and Welfare (Japan). Act on the Safety of Regenerative Medicine (English translation). Source (accessed October 24, 2026).
  22. Ministry of Health, Labour and Welfare (Japan). Information on regenerative medicine providers. Source (accessed October 24, 2026).
  23. Ministry of Health, Labour and Welfare (Japan). For International Visitors to Japan: We Strongly Recommend Enrolling in Private Health Insurance to Prepare for Medical Treatment During Your Stay. Source (accessed October 27, 2026).
  24. NHS England. Clinical commissioning policy: Haematopoietic stem cell transplantation (HSCT) (all ages). Updated September 2, 2025. Source (accessed October 24, 2026).
  25. HealthCare.gov. External Review. Source (accessed October 24, 2026).
  26. Medicare.gov. Filing an appeal. Source (accessed October 24, 2026).